Optimal target blood pressure for major adverse cardiovascular and cerebrovascular events in hypertensive patients: a nationwide population-based study.
Journal
Journal of hypertension
ISSN: 1473-5598
Titre abrégé: J Hypertens
Pays: Netherlands
ID NLM: 8306882
Informations de publication
Date de publication:
01 01 2022
01 01 2022
Historique:
pubmed:
23
8
2021
medline:
28
1
2022
entrez:
22
8
2021
Statut:
ppublish
Résumé
Generalizing an 'optimal' blood pressure (BP) level for individuals with hypertension remains controversial due to the implementation of different medical guidelines. This study investigated the association of BP with major adverse cardiovascular and cerebrovascular events (MACCE) and determined the optimal BP for patients with hypertension. A total of 934 179 individuals who received antihypertensive medications were selected from the National Health Insurance Service Examination Database between 2003 and 2011 in Korea. Their BP was measured at the index date, which was the first health examination. The study outcomes were MACCE, including acute myocardial infarction, heart failure, stroke, and all-cause mortality. The participants were monitored until in December, 2017. The hazard ratios were calculated using Cox proportional hazard models. The cumulative incidence of MACCE for each BP group was estimated using the Kaplan-Meier method. A lower risk of MACCE was observed at a SBP of 120-129 mmHg and a DBP of 80-89 mmHg. The endpoint-specific incidence rates and hazard ratios for acute myocardial infarction, heart failure, stroke, and all-cause mortality were the lowest at a SBP of 120-129 mmHg and a DBP of 80-89 mmHg. Even though this observational study did not support inference of a causal relationship, a SBP of 120-129 mmHg and a DBP of 80-89 mmHg may be safely recommended considering the possibility of MACCE in Korean patients with hypertension. In addition, the target BP should be tailored individually according to age, sex, and comorbidities.
Sections du résumé
BACKGROUND
Generalizing an 'optimal' blood pressure (BP) level for individuals with hypertension remains controversial due to the implementation of different medical guidelines. This study investigated the association of BP with major adverse cardiovascular and cerebrovascular events (MACCE) and determined the optimal BP for patients with hypertension.
METHOD
A total of 934 179 individuals who received antihypertensive medications were selected from the National Health Insurance Service Examination Database between 2003 and 2011 in Korea. Their BP was measured at the index date, which was the first health examination. The study outcomes were MACCE, including acute myocardial infarction, heart failure, stroke, and all-cause mortality. The participants were monitored until in December, 2017. The hazard ratios were calculated using Cox proportional hazard models. The cumulative incidence of MACCE for each BP group was estimated using the Kaplan-Meier method.
RESULTS
A lower risk of MACCE was observed at a SBP of 120-129 mmHg and a DBP of 80-89 mmHg. The endpoint-specific incidence rates and hazard ratios for acute myocardial infarction, heart failure, stroke, and all-cause mortality were the lowest at a SBP of 120-129 mmHg and a DBP of 80-89 mmHg.
CONCLUSION
Even though this observational study did not support inference of a causal relationship, a SBP of 120-129 mmHg and a DBP of 80-89 mmHg may be safely recommended considering the possibility of MACCE in Korean patients with hypertension. In addition, the target BP should be tailored individually according to age, sex, and comorbidities.
Identifiants
pubmed: 34420011
doi: 10.1097/HJH.0000000000002980
pii: 00004872-202201000-00010
doi:
Substances chimiques
Antihypertensive Agents
0
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
76-83Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Références
Fuchs FD, Whelton PK. High blood pressure and cardiovascular disease. Hypertension 2020; 75:285–292.
Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 2016; 387:957–967.
Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension. Overview, meta-analyses, and meta-regression analyses of randomized trials. J Hypertens 2014; 32:2285–2295.
Xie X, Atkins, Lv J, Bennett A, Neal B, Ninomiya T, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet 2016; 387:435–443.
Böhm M, Schumacher H, Teo KK, Lonn EM, Mahfoud F, Mann JFE, et al. Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials. Lancet 2017; 389:2226–2237.
Kalkman DN, Brouwer TF, Vehmeijer JT, Berger WR, Knops RE, Winter RJ, et al. Curve in patients randomly assigned to different systolic blood pressure targets: an experimental approach to an observational paradigm. Circulation 2017; 136:2220–2229.
Vidal-Petiot E, Ford I, Greenlaw N, Ferrari R, Fox KM, Tardif JC, et al. Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study. Lancet 2016; 388:2142–2152.
Messerli FH, Mancia G, Conti CR, Hewkin AC, Kupfer S, Champion A, et al. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med 2006; 144:884–893.
Williams B, Mancia G, Spiering W, Agabiti E, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. J Hypertens 2018; 36:1953–2041.
Kim JY, Ko GB, Lee TH, Park SH, Lee YN, Cho YS, et al. Partially covered metal stents may not prolong stent patency compared to uncovered stents in unresectable malignant distal biliary obstruction. Gut Liver 2017; 11:440–446.
Tsujimoto T, Kajio H. Intensive blood pressure treatment for resistant hypertension. Hypertension 2019; 73:415–423.
Mouhat B, Putot A, Hanon O, Eicher JC, Chagué F, Beer JC, et al. Low systolic blood pressure and mortality in elderly patients after acute myocardial infarction. J Am Heart Assoc 2020; 9:e013030.
Kim MK, Han K, Koh ES, Kim ES, Lee MK, Nam G, et al. Blood pressure and development of cardiovascular disease in koreans with type 2 diabetes mellitus. Hypertension 2019; 73:319–326.
Radovanovic D, Seifert B, Urban P, Eberli FR, Rickli H, Bertel O, et al. Charlson Comorbidity Index in patients hospitalized with acute coronary syndrome. Eur Heart J 2013; 34: (Suppl_1): P3122.
Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006; 145:247–254.
Sabaté S, Mases A, Guilera N, Canet J, Castillo J, Orrego C, et al. Incidence and predictors of major perioperative adverse cardiac and cerebrovascular events in noncardiac surgery. Br J Anaesth 2011; 107:879–890.
Davies WR, Brown AJ, Watson W, McCormick LM, West NE, Dutka DP, et al. Remote ischemic preconditioning improves outcome at 6 years after elective percutaneous coronary intervention: the CRISP stent trial long-term follow-up. Circulation 2013; 6:246–251.
Pappaccogli M, Di Monaco S, Perlo E, Burrello J, D’Ascenzo F, Veglio F, et al. Comparison of automated office blood pressure with office and out-off-office measurement techniques. Hypertension 2019; 73:481–490.
Roerecke M, Kaczorowski J, Myers MG. Comparing automated office blood pressure readings with other methods of blood pressure measurement for identifying patients with possible hypertension: a systematic review and meta-analysis. JAMA Intern Med 2019; 179:351–362.